| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tumor necrosis factor receptor superfamily member 9; 4-1BB ligand receptor; T-cell antigen 4-1BB; CD137; Tnfrsf9; Cd137; Ila; Ly63 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human ADAR1/ADAR recombinant protein (Position: M1-E1152). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-ADAR1/ADAR Antibody Picoband® is an antibody for ADAR detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, IF, ICC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: ADAR (TNF receptor superfamily member 9); UniProt: P55265
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 110 kDa
- Applications: WB, IHC, IF, ICC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-ADAR1/ADAR Antibody Picoband® catalog # A00869-2.
Biological background
Biological context: Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
Expression and localization notes: cellular localization: Membrane; Single-pass type I membrane protein., tissue context: Expressed on the surface of activated T-cells..
Common research applications
- Western blotting (WB): Compare ADAR levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of ADAR in tissue sections, considering fixation and antigen retrieval effects.
- Immunofluorescence / ICC: Assess subcellular localization patterns and co-localization with compartment markers in cultured cells.
- Flow cytometry: Quantify ADAR-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: Double-stranded RNA-specific adenosine deaminase is an enzyme that in humans is encoded by the ADAR gene. This gene encodes the enzyme responsible for RNA editing by site-specific deamination of adenosines. This enzyme destabilizes double-stranded RNA through conversion of adenosine to inosine. Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing results in multiple transcript variants.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Membrane; Single-pass type I membrane protein.
- Tissue details: Expressed on the surface of activated T-cells.
- Research category: Apoptosis,Associated Proteins,Cancer,Cell Biology,Cell Death,Cell Type Markers,Cytokines,Hematopoietic Progenitors,Immunology,Innate Immunity,Lymphoid,Receptors,Stem Cells,T Lymphocytic Lineage,TNF Superfamily,Tumor Immunology
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.